Emergent BioSolutions Inc... (EBS)
NYSE: EBS
· Real-Time Price · USD
6.29
-0.03 (-0.47%)
At close: Jun 02, 2025, 3:59 PM
6.23
-0.92%
After-hours: Jun 02, 2025, 06:49 PM EDT
Emergent BioSolutions Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Contracts and Grants Revenue | 30M | 26.3M | 41.4M | 71.3M |
| Contracts and Grants Revenue Growth | +14.07% | -36.47% | -41.94% | n/a |
| Service Revenue | 103.5M | 72.8M | 966.2M | n/a |
| Service Revenue Growth | +42.17% | -92.47% | n/a | n/a |
| Commercial Product Revenue | 398.9M | 497.3M | n/a | n/a |
| Commercial Product Revenue Growth | -19.79% | n/a | n/a | n/a |
| Product Revenue | 908.7M | 944.5M | n/a | n/a |
| Product Revenue Growth | -3.79% | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|
| Services Segment Revenue | 104.9M | 78.5M |
| Services Segment Revenue Growth | +33.63% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 52.4M | 60.8M | 76.6M | 77.3M | 84.6M | 87.5M | 86M | 91.4M | 100.5M | 94.2M | 80.2M | 81.1M | 84.8M | 94.2M | 82.1M | 91.2M | 80.9M | 82.1M | 75.5M | 76M | 69.7M | 72.2M | 65M | 70.8M | 65.4M | 81M | 42.1M | 39.51M | 40.2M | 41.98M | 34.5M | 31.87M | 35.15M | 35.36M | 40.69M | 44.15M | 39.78M | 45.96M | 31.56M | 36.45M | 34.49M |
| Selling, General, and Administrative Revenue Growth | -13.82% | -20.63% | -0.91% | -8.63% | -3.31% | +1.74% | -5.91% | -9.05% | +6.69% | +17.46% | -1.11% | -4.36% | -9.98% | +14.74% | -9.98% | +12.73% | -1.46% | +8.74% | -0.66% | +9.04% | -3.46% | +11.08% | -8.19% | +8.26% | -19.26% | +92.38% | +6.58% | -1.74% | -4.22% | +21.66% | +8.27% | -9.34% | -0.59% | -13.10% | -7.84% | +10.97% | -13.43% | +45.63% | -13.43% | +5.68% | n/a |
| Research and Development Revenue | 15.1M | 9.1M | 13.8M | 27.3M | 15M | 29.2M | 15.3M | 26M | 40.6M | 57.6M | 39.2M | 49.8M | 46.4M | 83M | 49.6M | 48.9M | 52.5M | 59.5M | 84.4M | 47.9M | 42.7M | 62.8M | 53.4M | 63.9M | 46.1M | 52M | 37.01M | 24.75M | 29.05M | 28.5M | 22.66M | 25.75M | 20.48M | 27.12M | 27.19M | 35.35M | 34.15M | 32.49M | 41.87M | 40.94M | 38.7M |
| Research and Development Revenue Growth | +65.93% | -34.06% | -49.45% | +82.00% | -48.63% | +90.85% | -41.15% | -35.96% | -29.51% | +46.94% | -21.29% | +7.33% | -44.10% | +67.34% | +1.43% | -6.86% | -11.76% | -29.50% | +76.20% | +12.18% | -32.01% | +17.60% | -16.43% | +38.61% | -11.35% | +40.52% | +49.55% | -14.82% | +1.94% | +25.77% | -12.01% | +25.76% | -24.49% | -0.26% | -23.08% | +3.49% | +5.13% | -22.41% | +2.26% | +5.79% | n/a |